60 Degrees Pharma (Nasdaq: SXTP) CEO Geoff Dow on Scaling ARAKODA Revenue + Babesiosis Upside
Feb. 19, 2026
In our exclusive interview, Geoff Dow, President and CEO of 60 Degrees Pharmaceuticals (Nasdaq: SXTP), breaks down the company’s commercial growth plan for ARAKODA® (tafenoquine) and the potential expansion into babesiosis, a tick-borne disease with no FDA-approved treatments today.
60 Degrees Pharma is already revenue-generating and is working to scale ARAKODA while advancing tafenoquine into a larger adjacent indication. The company also shared an early signal in its relapsing babesiosis study, reporting no Babesia infection detected in the first patient to complete therapy (reported October 2025).
